Devers Shannon L., an insider at Ionis Pharmaceuticals Inc (IONS), recently acquired 34,271 shares of the company at a price of $53.77 each, totaling $1.84 million. This transaction took place on November 24, 2025.
Following this purchase, Devers now holds 34,271 shares of Ionis Pharmaceuticals. The move underscores a potential confidence in the company's future, as insiders typically have access to non-public information that may influence their investment decisions.
Ionis Pharmaceuticals, headquartered in Carlsbad, California, specializes in developing and commercializing human therapeutic drugs using antisense technology. The company currently employs 1,069 full-time staff and has a market capitalization of $11.7 billion. Its marketed medicines include TRYNGOLZA, WAINUA, SPINRAZA, QALSODY, TEGSEDI, and WAYLIVRA, which target various serious health conditions.
While insider buying can be seen as a positive signal, it is important for investors to consider these transactions in context. Insider activity should be evaluated alongside other fundamental and technical indicators. Examining patterns of buying across multiple insiders over time provides a more comprehensive view of the company's outlook.
Ionis Pharmaceuticals is set to report its upcoming earnings on July 28, 2026, with an estimated EPS of -$0.74 and projected revenue of $214.6 million.